Hepatocellular carcinoma prevalence and mortality in a male state prison population

Public Health Reports

Volumn 124, Issue 1, 2009, Pages 120-126

  Baillargeon, Jacques ^a,b   Snyder, Ned ^a   Soloway, Roger D ^a   Paar, David ^a,b   Baillargeon, Gwen ^b   Spaulding, Anne C ^c   Pollock, Brad H ^d   Arcari, Christine M ^a   Williams, Brie A ^e   Raimer, Ben G ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CANCER MORTALITY; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PRISONER; SEROLOGY; UNITED STATES;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; HUMANS; INFORMATION SYSTEMS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PRISONERS; TEXAS; YOUNG ADULT;

EID: 66949124798     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/003335490912400115     Document Type: Article

References (29)

1. El-Serag HB, Davila JA, Peterson NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update [published erratum appears in Ann Intern Med 2004;140:151]. Ann Intern Med 2003;139:817-823
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750 (Pubitemid 29114292)
3. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006;15:1198-1203
4. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227-3230 (Pubitemid 30842426)
5. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-782 (Pubitemid 30118650)
6. Baillargeon J, Wu H, Kelley MJ, Grady J, Linthicum L, Dunn K. Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system. Public Health 2003;117:43-48 (Pubitemid 36336592)
7. Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons [published erratum appears in Am J Public Health 2004;94:1847]. Am J Public Health 2004;94:1218-1223
8. Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS 2005;19(Suppl 3):S41-6.
9. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562
10. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis 2002;35:305-312 (Pubitemid 34800280)
11. Baillargeon J, Soloway RD, Paar D, Giordano TP, Murray O, Grady J, et al. End-stage liver disease in a state prison population. Ann Epidemiol 2007;17:808-813 (Pubitemid 47393635)
12. Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: a systematic review. Addiction 2006;101:181-191 (Pubitemid 43351593)
13. Peters RH, Greenbaum PE, Edens JF, Carter CR, Ortiz MM. Prevalence of DSM-IV substance abuse and dependence disorders among prison inmates. Am J Drug Alcohol Abuse 1998;24:573-587 (Pubitemid 28531730)
14. SAS Institute, Inc. SAS: Version 8.0. Cary (NC): SAS Institute, Inc.; 1999.
15. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al., editors. Surveillance epidemiology and end results (SEER) cancer statistics review, 1975-2004. Bethesda (MD): National Cancer Institute; 2007. Also available from: URL: http://seer.cancer.gov/ csr/1975-2004 [based on November 2006 SEER data submission, posted to the SEER website, 2007] [cited 2007 Nov 1].
16. Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006;25:3771-3777 (Pubitemid 43980472)
17. Braithwaite RL, Hammett TM, Mayberry RM. Prisons and AIDS: a public health challenge. San Francisco: Jossey-Bass Publishers; 1996.
18. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37(Suppl 2):S88-94.
19. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127(5 Suppl 1):S27-34. (Pubitemid 39423367)
20. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714
21. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-1213 (Pubitemid 35253437)
22. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-1268
23. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524
24. Degos F, Tural C. Hepatocellular carcinoma in human immunodeficiency virus (HIV)-infected patients: is it really different, and if so, why? J Hepatol 2007;47:447-450 (Pubitemid 47334761)
25. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497 (Pubitemid 32173638)
26. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, García- Bengoechea M, Hernández-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally- acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5. (Pubitemid 27072597)
27. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-1058 (Pubitemid 29458296)
28. Telfer PT, Brown D, Devereaux H, Lee CA, DuSheiko GM. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients. Br J Haematol 1994;88:397-399 (Pubitemid 24318193)
29. Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JH. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989;97:1559-1561 (Pubitemid 20004186)